​​​​​​​Triggering a huge afterhours selloff, Gaithersburg, MD-based Novavax reported on Thursday that its Phase III RSV vaccine candidate flunked a big Phase…

GlaxoSmithKline's shingles vaccine candidate has staying power. According to new data, Shingrix protects for at least four years, a claim that Merck'…

The vaccines industry is set for consolidation, according to Serum Institute of India CEO Adar Poonawalla, who hopes his company will be on the buying end and…

Meriden, CT’s Protein Sciences has won what could become a major lifeline as it looks to grow slow sales for its Flublok influenza vaccine.

Just days after inking a $312M ZIka R&D deal, Takeda took a step toward challenging Sanofi’s first-to-market dengue vaccine on Wednesday, kicking off a…

One year into a meningitis B vaccination campaign in the U.K., GlaxoSmithKline is touting promising preliminary data that may help to build the vaccine’s case…

Already facing a slower-than-expected launch, Sanofi’s $1.5 billion dengue vaccine Dengvaxia could do more harm than good if used in the wrong setting, a new…

Plans are being laid for India and the U.S. to work together on the development of vaccines for dengue fever and other diseases that pose a major threat to…